Statistiche di base
| LEI | 254900EIUFZTW136H859 |
| CIK | 1801198 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Legend Biotech Corporation - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 18, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Translation of registrant's name into English) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principal |
|
| August 18, 2025 |
Legend Biotech Appoints Carlos Santos as Chief Financial Officer EXHIBIT 99.1 Legend Biotech Appoints Carlos Santos as Chief Financial Officer SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company’s Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie Yeung, who has served as t |
|
| August 11, 2025 |
legn2qpipelineslide 1 *In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: August 11, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princ |
|
| August 11, 2025 |
Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights •CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $439 million •CARVYKTI® demonstrated positive long-term outcomes in CARTITUDE-1 study with one-third of patients remaining progression-free for ≥5 years •Presented other important CARVYKTI® and new solid tumor data at ASCO •Over 7,500 patients treated to date •Cash and cash equivalents, and time deposits of $1. |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: July 16, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princip |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: June 30, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princip |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: June 12, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princip |
|
| June 12, 2025 |
Voting Results of 2025 Annual General Meeting Exhibit 99.1 Voting Results of 2025 Annual General Meeting At Legend Biotech Corporation’s (the “Company”) annual general meeting of shareholders held on June 12, 2025 (the “AGM”), the Company’s shareholders: · received the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2024; · ratified the appointment of Ernst & Young LLP as the Company’s independe |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: June 6, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| June 6, 2025 |
Exhibit 99.1 1 Legend Biotech CORPORATE PRESENTATION JUNE 2025 2 Disclaimer This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the “Company”) solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been estab |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: June 5, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 3, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Translation of registrant's name into English) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principal ex |
|
| June 3, 2025 |
EXHIBIT 99.1 Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ≥5 years CARTITUDE-4 subgroup analyses featured in a poster presen |
|
| May 23, 2025 |
EXHIBIT 99.1 Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® infusion New data at ASCO from the CARTITUDE-4 study to showcase improved progression- |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 22, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Translation of registrant's name into English) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principal e |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: May 14, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| May 13, 2025 |
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights Legend Biotech Reports First Quarter 2025 Results and Recent Highlights •CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 million •Over 6,000 patients treated to date •Initiated CARVYKTI® clinical production at the Tech Lane facility •Received positive CHMP opinion to add statistically significant improvement in overall survival from CARTITUDE-4 study to CARVYKTI® label •Australia’s TGA approved CARVYKTI® in second-line plus settings for multiple myeloma patients •Cash and cash equivalents, and time deposits of $1. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: May 13, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| May 13, 2025 |
Exhibit 99.5 International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects. We operate in a global economy, and our business depends on a global supply chain for the development, manufacturing, and distribution of our pharmaceutical products, and for the advancement of our preclinical and cl |
|
| May 13, 2025 |
1 *In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. †Phase 1 investigator-initiated trial. ‡IND applications have been cleared by the U.S. FDA. #Subject to an exclusive license agreement with Novartis Pharma AG. The safety and efficacy of the agents and/or uses under investigation have not been established. There is no assurance that the agents will receive health auth |
|
| May 12, 2025 |
Exhibit 99.2 LEGEND BIOTECH CORPORATION (Incorporated in the Cayman Islands with limited liability) 2101 Cottontail Lane Somerset, New Jersey 08873 NOTICE OF ANNUAL GENERAL MEETING to Be Held on June 12, 2025 NOTICE IS HEREBY GIVEN that an Annual General Meeting (“AGM”) of Legend Biotech Corporation (the “Company”) will be held at the offices of the Company located at 2101 Cottontail Lane, Somerse |
|
| May 12, 2025 |
Exhibit 99.4 JPMorgan Chase Bank, N.A., Depositary PO Box 64873 Saint Paul MN 55164-0873 Legend Biotech Corporation TO THE REGISTERED HOLDERS OF AMERICAN DEPOSITARY RECEIPTS REPRESENTING ORDINARY SHARES OF Legend Biotech Corporation Please refer to the reverse side of this card for the Resolutions to be voted at the Meeting. FOLD AND DETACH HERE Ordinary Resolutions The Board of Director |
|
| May 12, 2025 |
LEGEND BIOTECH CORPORATION (the “Company”) P R O X Y Exhibit 99.3 LEGEND BIOTECH CORPORATION (the “Company”) P R O X Y I/We of , the holder of ordinary shares1 in the Company, hereby appoint the Chairperson of the Annual General Meeting2 or of as my/our proxy to vote on my/our behalf in respect of all matters and resolutions to be submitted for consideration and approval at the A |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: May 12, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| May 12, 2025 |
LEGEND BIOTECH CORPORATION 2101 Cottontail Lane Somerset, New Jersey 08873 PROXY STATEMENT Exhibit 99.1 LEGEND BIOTECH CORPORATION 2101 Cottontail Lane Somerset, New Jersey 08873 PROXY STATEMENT General The board of directors of Legend Biotech Corporation (the “Company”) is soliciting proxies for the annual general meeting of shareholders of the Company to be held on June 12, 2025 at 9:00 a.m. (local time) (the “AGM”). The AGM will be held at the offices of the Company located at 2101 C |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: April 15, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| March 11, 2025 |
Consent of Independent Registered Public Accounting Firm EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Post-Effective Amendment No. 1 to the Registration Statement (Form S-8 No. 333-239478) pertaining to the Share Option Scheme and the 2020 Restricted Shares Plan of Legend Biotech Corporation, (2) Registration Statement (Form F-3 No.333-257 |
|
| March 11, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jessie Yeung, certify that: 1.I have reviewed this annual report on Form 20-F (this “report”) of Legend Biotech Corp.(the “Company”); 2.Based on my knowledge, this report does not contain any untrue s |
|
| March 11, 2025 |
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights EXHIBIT 99.1 Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectively Over 5,000 patients treated to date Initiated commercial production of CARVYKTI® at a Novartis production facility Spain's national health system approved reimbursement fo |
|
| March 11, 2025 |
FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 4.4 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT (this “Amendment”) to that certain Amended and Restated Employment Agreement, dated August 1, 2022 (the “Employment Agreement”) by and between Legend Biotech USA Inc, together with its subsidiaries and parent company, Legend Biotech Corporation (collectively, the “Company”), and Ying Huang, Ph.D. (the “Ex |
|
| March 11, 2025 |
AMENDMENT 1 TO LICENSE AGREEMENT CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. |
|
| March 11, 2025 |
Exhibit 11.1 Conduct OUR CODE Our commitment to doing the right thing OUR CODE | 2 Table of Contents A Message from Our CEO 3 Our Code 4 Corporate Compliance Program 6 Reporting Concerns 6 No Retaliation 7 Compliance with Laws and Regulations 8 Corruption, Bribery and Transparency 8 Anti-Money Laundering 9 Gifts and Entertainment 9 Healthcare Community Engagement 9 Conflicts of Interest 10 Identif |
|
| March 11, 2025 |
LEASE AGREEMENT BY AND BETWEEN GENSCRIPT USA HOLDING, INC. LEGEND BIOTECH USA INC. Exhibit 4.8 LEASE AGREEMENT BY AND BETWEEN GENSCRIPT USA HOLDING, INC. Lessor AND LEGEND BIOTECH USA INC. Lessee Dated: As of January 1, 2024 THIS LEASE, made effective as of January 1, 2024, between GenScript USA Holding, Inc. with an office at 860 Centennial Ave., Piscataway, New Jersey 08854 (hereinafter called "Lessor") and Legend Biotech USA Inc. with an office at 2101 Cottontail Lane, Somers |
|
| March 11, 2025 |
LEGEND BIOTECH CORPORATION 2020 RESTRICTED SHARES PLAN AS AMENDED AND RESTATED ARTICLE 1 Exhibit 4.9 LEGEND BIOTECH CORPORATION 2020 RESTRICTED SHARES PLAN AS AMENDED AND RESTATED ARTICLE 1 PURPOSE The purpose of the Legend Biotech Corporation 2020 Restricted Shares Plan as amended and restated (the “Plan”) is to promote the success and enhance the value of Legend Biotech Corporation, an exempted company incorporated under the laws of the Cayman Islands (the “Company”), by linking the |
|
| March 11, 2025 |
LEGEND BIOTECH CORPORATION INSIDER TRADING POLICY Exhibit 11. LEGEND BIOTECH CORPORATION INSIDER TRADING POLICY 1.PURPOSE The purpose of this Insider Trading Policy (this “Policy”) is to ensure that Legend Biotech Corporation and its subsidiaries and controlled affiliates (collectively, the “Company”) and all of the Company’s directors, officers and employees comply with all applicable laws, rules and regulations regarding “insider trading.” 2.SC |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| March 11, 2025 |
MASTER MANUFACTURING AND SUPPLY SERVICES AGREEMENT FOR BCMA CAR-T PRODUCT Exhibit 4.27 Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) is the type that the registrant treats as private or confidential. MASTER MANUFACTURING AND SUPPLY SERVICES AGREEMENT FOR BCMA CAR-T PRODUCT This Master Manufacturing and Supply Services Agreement for BCMA CAR-T Product is effective as of the date of l |
|
| March 11, 2025 |
CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. |
|
| March 11, 2025 |
CERTAIN INFORMATION (INDICATED BY “[***]”) HAS BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE (I) SUCH INFORMATION IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. |
|
| March 11, 2025 |
Legend Biotech Corporation Non-Employee Director Compensation Policy EXHIBIT 4.11 Legend Biotech Corporation Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Legend Biotech Corporation (the “Company”) and is not affiliated with an entity that beneficially owns 5% or more of the Company’s outstanding share capital (each such member, an “Eligible Director”) will receive the compens |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 11, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Translation of registrant's name into English) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principal |
|
| March 11, 2025 |
Legend Biotech Corporation Incentive Compensation Recoupment Policy Exhibit 4.25 Legend Biotech Corporation Incentive Compensation Recoupment Policy 1.Introduction The Board of Directors (the “Board”) of Legend Biotech Corporation, an exempted company incorporated under the laws of the Cayman Islands with limited liability (the “Company”), has determined that it is in the best interests of the Company and its shareholders to adopt this Incentive Compensation Recou |
|
| March 11, 2025 |
CLINICAL SUPPLY SERVICES AGREEMENT FOR BCMA CAR-T PRODUCT Exhibit 4.23 CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. CLINICAL SUPPLY SERVICES AGREEMENT FOR BCMA CAR-T PRODUCT This amendment #1 (hereinafter “Amendment”) is effective as of the date of last signature below and ent |
|
| March 11, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ying Huang, certify that: 1.I have reviewed this annual report on Form 20-F (this “report”) of Legend Biotech Corp.(the “Company”); 2.Based on my knowledge, this report does not contain any untrue sta |
|
| March 11, 2025 |
EXHIBIT 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Legend Biotech Corp. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ying Hua |
|
| March 11, 2025 |
EXHIBIT 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Legend Biotech Corp. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jessie Y |
|
| March 11, 2025 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act Exhibit 2.4 Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act As of December 31, 2024, Legend Biotech Corporation (the “Company,” “we,” “us” and “our”) had the following series of securities registered pursuant to Section 12 of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American depositary shares, each |
|
| March 11, 2025 |
CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. |
|
| March 11, 2025 |
CERTAIN INFORMATION (INDICATED BY “[***]”) HAS BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE (I) SUCH INFORMATION IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: January 22, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: January 14, 2025 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| January 14, 2025 |
Exhibit 99.1 1 Legend Biotech CORPORATE PRESENTATION JANUARY 14, 2025 2 Disclaimer This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the “Company”) solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not bee |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: December 23, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of pri |
|
| December 23, 2024 |
Exhibit 99.1 December 18, 2024 Lori Macomber Re: Transition Agreement Dear Lori: This letter sets forth the substance of the transition agreement (the “ Agreement ”) which Legend Biotech USA Inc . (the “ Company ”) is offering to you to aid in your employment transition . This Agreement will become effective on the date it has been signed by both parties (the “ Effective Date ”) . 1. Transition Pe |
|
| December 10, 2024 |
EXHIBIT 99.1 CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma 89 percent of evaluable patients achieved minimal residual disease (MRD) negativity with CARVYKTI® after three-year follow-up in CARTITUDE-4 study; the majority in less than 2 months Results add to the overall survival (OS) benefit |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 9, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Translation of registrant's name into English) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| November 14, 2024 |
As filed with the Securities and Exchange Commission on November 14, 2024 As filed with the Securities and Exchange Commission on November 14, 2024 Registration No. |
|
| November 14, 2024 |
LEGEND BIOTECH CORPORATION 2020 RESTRICTED SHARES PLAN AS AMENDED AND RESTATED ARTICLE 1 Exhibit 4.4 LEGEND BIOTECH CORPORATION 2020 RESTRICTED SHARES PLAN AS AMENDED AND RESTATED ARTICLE 1 PURPOSE The purpose of the Legend Biotech Corporation 2020 Restricted Shares Plan as amended and restated (the “Plan”) is to promote the success and enhance the value of Legend Biotech Corporation, an exempted company incorporated under the laws of the Cayman Islands (the “Company”), by linking the |
|
| November 14, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, par value US$0. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: November 12, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of pri |
|
| November 12, 2024 |
1 This presentation is for investor relations purposes only - Not for product promotional purposes Our Pipeline *In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. |
|
| November 12, 2024 |
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights •CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) updates: ◦Net trade sales of approximately $286 million, representing operational growth of 87. |
|
| November 5, 2024 |
EXHIBIT 99.1 Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma MRD data to be featured in oral presentation at the 66th Annual American Societ |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 5, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Translation of registrant's name into English) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: October 22, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: October 21, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| October 21, 2024 |
Voting Results of 2024 Annual General Meeting Exhibit 99.1 Voting Results of 2024 Annual General Meeting At Legend Biotech Corporation’s (the “Company”) annual general meeting of shareholders held on October 21, 2024 (the “AGM”), the Company’s shareholders: • received the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2023; • ratified the appointment of Ernst & Young LLP as the Company’s indepe |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: October 15, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: September 27, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Translation of registrant's name into English) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| September 27, 2024 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line Landmark CARTITUDE-4 study results show CARVYKTI® reduced the risk of death by 45 percent after three-year follow-up Late-breaking data featured in an oral presentation at the 21s |
|
| September 20, 2024 |
LEGEND BIOTECH CORPORATION 2101 Cottontail Lane Somerset, New Jersey 08873 PROXY STATEMENT EX-99.1 Exhibit 99.1 LEGEND BIOTECH CORPORATION 2101 Cottontail Lane Somerset, New Jersey 08873 PROXY STATEMENT General The board of directors of Legend Biotech Corporation (the “Company”) is soliciting proxies for the annual general meeting of shareholders of the Company to be held on October 21, 2024 at 9:30 a.m. (local time) (the “AGM”). The AGM will be held at the offices of the Company locate |
|
| September 20, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: September 20, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address o |
|
| September 20, 2024 |
LEGEND BIOTECH CORPORATION (the “Company”) P R O X Y EX-99.3 Exhibit 99.3 LEGEND BIOTECH CORPORATION (the “Company”) P R O X Y I/We of , the holder of ordinary shares1 in the Company, hereby appoint the Chairperson of the Annual General Meeting2 or of as my/our proxy to vote on my/our behalf in respect of all matters and resolutions to be submitted for consideration and |
|
| September 20, 2024 |
EX-99.2 Exhibit 99.2 LEGEND BIOTECH CORPORATION (Incorporated in the Cayman Islands with limited liability) 2101 Cottontail Lane Somerset, New Jersey 08873 NOTICE OF ANNUAL GENERAL MEETING to Be Held on October 21, 2024 NOTICE IS HEREBY GIVEN that an Annual General Meeting (“AGM”) of Legend Biotech Corporation (the “Company”) will be held at the offices of the Company located at 2101 Cottontail La |
|
| September 20, 2024 |
EX-99.4 Exhibit 99.4 Legend Biotech Corporation - Proof 3 17-Sep-24 JPMorgan Chase Bank, N.A., Depositary PO Box 64873 Saint Paul MN 55164-0873 Legend Biotech Corporation TO THE REGISTERED HOLDERS OF AMERICAN DEPOSITARY RECEIPTS REPRESENTING ORDINARY SHARES OF Legend Biotech Corporation Please refer to the reverse side of this card for the Resolutions to be voted at the Meeting. FOLD AND DETACH HE |
|
| September 11, 2024 |
CORRESP Mark Ballantyne (703) 456-8084 [email protected] VIA EDGAR September 11, 2024 Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attn: Jessica Dickerson Tim Buchmiller Re: Legend Biotech Corporation Form 20-F for Fiscal Year Ended December 31, 2023 Filed March 19, 2024 File No. 001-39307 Ladies and Gent |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: August 27, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princ |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: August 9, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| August 9, 2024 |
1 This presentation is for investor relations purposes only - Not for product promotional purposes Our Pipeline *In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. |
|
| August 9, 2024 |
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights •CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 million •MHRA and Health Canada approved CARVYKTI® in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma •CARVYKTI® demonstrates positive overall survival results in second interim analysis of CARTITUDE-4 study •Cash and cash equivalents, deposits and short-term investments of $1. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 8, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Translation of registrant's name into English) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principal |
|
| August 8, 2024 |
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors EXHIBIT 99.1 Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors SOMERSET, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Peter Salovey, Ph.D., President Emeritus of Yale University, to its Board of Directors. Dr. Salovey will serve as an independent director, |
|
| July 26, 2024 |
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024 EXHIBIT 99.1 Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024 SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months ended June 30, 2024. For the six-months ended June 30, 2024, Legend Biotech expects t |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 26, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Translation of registrant's name into English) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principal e |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: July 17, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princip |
|
| July 2, 2024 |
EXHIBIT 99.1 Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell the |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 2, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Translation of registrant's name into English) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principal ex |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: June 3, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| June 3, 2024 |
Exhibit 99.1 Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA · First analysis of CARTITUDE-2 Cohort D study investigating CARVYKTI® in multiple myeloma with suboptimal response after front-line ASCT featured in an oral presentation at the 2024 ASCO Annual Meeting show deep and durable responses |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: May 23, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| May 23, 2024 |
EXHIBIT 99.1 Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA First disclosure from Cohort D of the Phase 2 CARTITUDE-2 study investigating CARVYKTI® in patients who had suboptimal response to frontline ASCT in an oral presentation at ASCO & EHA An oral presentation at ASCO of data from the Phase 3 CARTITUDE-4 study evaluating CARVYKTI |
|
| May 13, 2024 |
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights Legend Biotech Reports First Quarter 2024 Results and Recent Highlights •CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $157 million •EC and US FDA approved CARVYKTI® label expansion in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma •Legend and Johnson & Johnson enter into Master Manufacturing and Supply Services Agreement with Novartis Pharmaceuticals Corporation •On April 5, Legend Biotech earned a milestone payment of $45 million in connection with FDA’s approval of CARVYKTI’s label expansion to treat 2L+ MM, in accordance with the Janssen Agreement* •Cash and cash equivalents, deposits and short-term investments of $1. |
|
| May 13, 2024 | ||
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: May 13, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: April 22, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| April 22, 2024 |
Exhibit 99.1 CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse SOMERSET, N.J. – April 22, 2024 – Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: April 16, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| April 8, 2024 |
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse SOMERSET, N. |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: April 5, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princip |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: March 29, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| March 19, 2024 |
Legend Biotech Corporation Dated as of , 20 Debt Securities Exhibit 4.4 Legend Biotech Corporation Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.01 Designation and Terms of Securities 3 Section 2.02 Form of Securities and Trustee’s Certificate 5 Sect |
|
| March 19, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ying Huang, certify that: 1.I have reviewed this annual report on Form 20-F (this “report”) of Legend Biotech Corp.(the “Company”); 2.Based on my knowledge, this report does not contain any untrue sta |
|
| March 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Debt Debt Securities Rule 456(b) and Rule 457(r) (1) (1) (1) (2) (2) Equity Ordinary Shares, par value $0. |
|
| March 19, 2024 |
As filed with the Securities and Exchange Commission on March 19, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 19, 2024 Registration No. |
|
| March 19, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lori Macomber, certify that: 1.I have reviewed this annual report on Form 20-F (this “report”) of Legend Biotech Corp.(the “Company”); 2.Based on my knowledge, this report does not contain any untrue |
|
| March 19, 2024 |
Legend Biotech Corporation Non-Employee Director Compensation Policy EXHIBIT 4.11 Legend Biotech Corporation Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Legend Biotech Corporation (the “Company”) and is not affiliated with an entity that beneficially owns 5% or more of the Company’s outstanding share capital (each such member, an “Eligible Director”) will receive the compens |
|
| March 19, 2024 |
EXHIBIT 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Legend Biotech Corp. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lori Mac |
|
| March 19, 2024 |
CLINICAL SUPPLY SERVICES AGREEMENT FOR BCMA CAR-T PRODUCT Exhibit 4.23 CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. CLINICAL SUPPLY SERVICES AGREEMENT FOR BCMA CAR-T PRODUCT This amendment #1 (hereinafter “Amendment”) is effective as of the date of last signature below and ent |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| March 19, 2024 |
Exhibit 4.7 LEGEND BIOTECH CORPORATION AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF LEGEND BIOTECH CORPORATION FORM OF DEBT SECURITIES WARRANT AGREEMENT This Debt Securities Warrant Agreement (this “Agreement”), dated as of [•], between LEGEND BIOTECH CORPORATION, an exempted company incorporated in the Cayman Islands with limited liability and having its registered |
|
| March 19, 2024 |
Consent of Independent Registered Public Accounting Firm EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Post-Effective Amendment No. 1 to the Registration Statement (Form S-8 No. 333-239478) pertaining to the Share Option Scheme and the 2020 Restricted Shares Plan of Legend Biotech Corporation, (2) Registration Statement (Form F-3 No.333-257 |
|
| March 19, 2024 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act Exhibit 2.4 Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act As of December 31, 2023, Legend Biotech Corporation (the “Company,” “we,” “us” and “our”) had the following series of securities registered pursuant to Section 12 of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American depositary shares, each |
|
| March 19, 2024 |
FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 4.6 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT (this “Amendment”) to that certain Amended and Restated Employment Agreement, dated September 28, 2022 (the “Employment Agreement”) by and between Legend Biotech USA Inc, together with its subsidiaries and parent company, Legend Biotech Corporation (the “Company”), and Lori Macomber (the “Executive”), is |
|
| March 19, 2024 |
Exhibit 4.6 LEGEND BIOTECH CORPORATION AND , AS WARRANT AGENT FORM OF ORDINARY SHARES WARRANT AGREEMENT DATED AS OF LEGEND BIOTECH CORPORATION FORM OF ORDINARY SHARES WARRANT AGREEMENT THIS ORDINARY SHARES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Legend Biotech Corporation, an exempted company incorporated in the Cayman Islands with limited liability and having its registered |
|
| March 19, 2024 |
CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. |
|
| March 19, 2024 |
Exhibit 11.1 Conduct OUR CODE Our commitment to doing the right thing OUR CODE | 2 Table of Contents A Message from Our CEO 3 Our Code 4 Corporate Compliance Program 6 Reporting Concerns 6 No Retaliation 7 Compliance with Laws and Regulations 8 Corruption, Bribery and Transparency 8 Anti-Money Laundering 9 Gifts and Entertainment 9 Healthcare Community Engagement 9 Conflicts of Interest 10 Identif |
|
| March 19, 2024 |
CERTAIN INFORMATION (INDICATED BY “[***]”) HAS BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE (I) SUCH INFORMATION IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. |
|
| March 19, 2024 |
EXHIBIT 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Legend Biotech Corp. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ying Hua |
|
| March 19, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Post-Effective Amendment No. 1 to the Registration Statement (Form S-8 No. 333-239478) pertaining to the Share Option Scheme and the 2020 Restricted Shares Plan of Legend Biotech Corporation, (2) Registration Statement (Form F-3 No.333-257 |
|
| March 19, 2024 |
FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 4.4 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT (this “Amendment”) to that certain Amended and Restated Employment Agreement, dated August 1, 2022 (the “Employment Agreement”) by and between Legend Biotech USA Inc, together with its subsidiaries and parent company, Legend Biotech Corporation (collectively, the “Company”), and Ying Huang, Ph.D. (the “Ex |
|
| March 19, 2024 |
Legend Biotech Corporation Incentive Compensation Recoupment Policy Exhibit 4.25 Legend Biotech Corporation Incentive Compensation Recoupment Policy 1.Introduction The Board of Directors (the “Board”) of Legend Biotech Corporation, an exempted company incorporated under the laws of the Cayman Islands with limited liability (the “Company”), has determined that it is in the best interests of the Company and its shareholders to adopt this Incentive Compensation Recou |
|
| March 15, 2024 |
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma FDA ODAC votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI based on results from the Phase 3 CARITUDE-4 study SOMERSET, N.J. – March 15, 2024 – Legend Biotech Corporation (NASDAQ: LEGN) (L |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: March 15, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: March 13, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: March 11, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| March 11, 2024 | ||
| March 11, 2024 |
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights •CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $159 million and $500 million for the fourth quarter and full year 2023, respectively •CHMP recommended CARVYKTI® label expansion in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma. |
|
| February 23, 2024 |
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy CARVYKTI® is the first CAR-T therapy for patients with relapsed and refractory multiple myeloma to receive a positive CHMP opinion for second line treatment SOMERSET, N. |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: February 23, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of pri |
|
| February 14, 2024 |
SC 13G/A 1 p24-0549sc13ga.htm LEGEND BIOTECH CORP SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Legend Biotech Corporation (Name of Issuer) Ordinary Shares, par value of $0.0001 per share (Title of Class of Securities) 52490G102** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Sta |
|
| February 14, 2024 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Legend Biotech Corporation (Name of Issuer) Ordinary Shares (Title of Class of Securities) 52490G102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuan |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: January 23, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: January 23, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: January 9, 2024 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princ |
|
| January 9, 2024 |
Exhibit 99.1 Legend Biotech Corporate Presentation This presentation is for investor relations purposes only – Not for product promotional purposes JANUARY 2024 Disclaimer 3 This presentation is for investor relations purposes only – Not for product promotional purposes This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the “Company”) solely for information purp |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: December 21, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of pri |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: December 21, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of pri |
|
| December 12, 2023 |
Exhibit 99.1 Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel) In CARTITUDE-4, CARVYKTI® demonstrated clinically meaningful improvements in patient-reported outcomes when compared to standard of care The as-treated |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: December 11, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of pri |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: November 20, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of pri |
|
| November 20, 2023 |
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights •Legend Biotech Corporation (the “Company” or Legend Biotech), through its wholly owned subsidiary, Legend Biotech Ireland Limited, entered into an exclusive, global license agreement with Novartis Pharma AG. |
|
| November 20, 2023 | ||
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: November 13, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of pri |
|
| November 13, 2023 |
Exhibit 99.1 Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3 The deal with Novartis seeks to advance Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies targeting Delta-like ligand protein 3 (DLL3), using the Novartis next-generation T-Charge™ CAR-T cell therapy platform Legend Biotech wi |
|
| October 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: October 17, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: September 25, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of pr |
|
| September 25, 2023 |
Voting Results of 2023 Annual General Meeting Exhibit 99.1 Voting Results of 2023 Annual General Meeting At Legend Biotech Corporation’s (the “Company”) annual general meeting of shareholders held on September 21, 2023 (the “AGM”), the Company’s shareholders: • received the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2022; • ratified the appointment of Ernst & Young LLP as the Company’s inde |
|
| September 8, 2023 |
September 8, 2023 Division of Corporation Finance Disclosure Review Program U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attn: Christopher Dunham Andrew Mew Re: Legend Biotech Corporation Form 20-F for Fiscal Year Ended December 31, 2022 Filed March 30, 2023 File No. 001-39307 Ladies and Gentlemen: On behalf of our client Legend Biotech Corporation (the “Company”), |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: August 28, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princ |
|
| August 21, 2023 |
Exhibit 99.2 LEGEND BIOTECH CORPORATION (Incorporated in the Cayman Islands with limited liability) 2101 Cottontail Lane Somerset, New Jersey 08873 NOTICE OF ANNUAL GENERAL MEETING to Be Held on September 21, 2023 NOTICE IS HEREBY GIVEN that an Annual General Meeting (“AGM”) of Legend Biotech Corporation (the “Company”) will be held at the offices of the Company located at 2101 Cottontail Lane, So |
|
| August 21, 2023 |
LEGEND BIOTECH CORPORATION 2101 Cottontail Lane Somerset, New Jersey 08873 PROXY STATEMENT Exhibit 99.1 LEGEND BIOTECH CORPORATION 2101 Cottontail Lane Somerset, New Jersey 08873 PROXY STATEMENT General The board of directors of Legend Biotech Corporation (the “Company”) is soliciting proxies for the annual general meeting of shareholders of the Company to be held on September 21, 2023 at 9:30 a.m. (local time) (the “AGM”). The AGM will be held at the offices of the Company located at 2 |
|
| August 21, 2023 |
Exhibit 99.4 JPMorgan Chase Bank, N.A., Depositary PO Box 64873 Saint Paul MN 55164-0873 Legend Biotech Corporation TO THE REGISTERED HOLDERS OF AMERICAN DEPOSITARY RECEIPTS REPRESENTING ORDINARY SHARES OF Legend Biotech Corporation Please refer to the reverse side of this card for the Resolutions to be voted at the Meeting. FOLD AND DETACH HERE Ordinary Resolutions The Board of Directors unanimou |
|
| August 21, 2023 |
LEGEND BIOTECH CORPORATION (the “Company”) P R O X Y Exhibit 99.3 LEGEND BIOTECH CORPORATION (the “Company”) P R O X Y I/We of , the holder of ordinary shares1 in the Company, hereby appoint the Chairperson of the Annual General Meeting2 or of as my/our proxy to vote on my/our behalf in respect of all matters and resolutions to be submitted for consideration and approval at the Annual General Meeting of the Company to be held on the 21st day of Sept |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: August 21, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princ |
|
| August 15, 2023 |
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights •A supplemental Biologics License Application (sBLA) was submitted to the U. |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: August 15, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princ |
|
| August 15, 2023 |
a994pipeline |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: July 20, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princip |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: June 6, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| June 6, 2023 |
Exhibit 99.1 Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) The application is supported by the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival compared to standard regimens CARTITUDE-4 is the first randomized Phase 3 study investigating the ef |
|
| June 5, 2023 |
Exhibit 99.1 Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study First analysis data from CARTITUDE-4 demonstrated a statistically significant improvement in progression-free survival, with a hazard ratio of 0.26 CARTITUDE-4 is the first randomized study |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: June 5, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| May 26, 2023 |
As filed with the Securities and Exchange Commission on May 26, 2023 F-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 26, 2023 Registration No. |
|
| May 26, 2023 |
EX-4.5 Exhibit 4.5 SUBSCRIPTION AGREEMENT dated as of April 19, 2023 by and between RA CAPITAL HEALTHCARE FUND, L.P. and LEGEND BIOTECH CORPORATION TABLE OF CONTENTS Page Article I DEFINITIONS AND INTERPRETATION 1 Section 1.1 Definitions 1 Section 1.2 Other Defined Terms 3 Section 1.3 Interpretation and Rules of Construction 4 Article II PURCHASE AND SALE OF SECURITIES 5 Section 2.1 Sale and Issua |
|
| May 26, 2023 |
EX-4.6 Exhibit 4.6 SUBSCRIPTION AGREEMENT dated as of April 26, 2023 by and between LGN HOLDINGS LIMITED and LEGEND BIOTECH CORPORATION TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INTERPRETATION 1 Section 1.1 Definitions 1 Section 1.2 Other Defined Terms 3 Section 1.3 Interpretation and Rules of Construction 4 ARTICLE II PURCHASE AND SALE OF SECURITIES 5 Section 2.1 Sale and Issuance of the P |
|
| May 26, 2023 |
EX-4.7 Exhibit 4.7 SUBSCRIPTION AGREEMENT dated as of May 19, 2023 by and between LGN HOLDINGS LIMITED and LEGEND BIOTECH CORPORATION TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INTERPRETATION 1 Section 1.1 Definitions 1 Section 1.2 Other Defined Terms 3 Section 1.3 Interpretation and Rules of Construction 4 ARTICLE II PURCHASE AND SALE OF SECURITIES 5 Section 2.1 Sale and Issuance of the Pur |
|
| May 26, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered((2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity Ordinary shares, par value $0. |
|
| May 25, 2023 |
6-K 1 a53406865.htm LEGEND BIOTECH CORPORATION 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: May 25, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail L |
|
| May 25, 2023 |
Exhibit 99.1 Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma who received one t |
|
| May 18, 2023 |
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights Exhibit 99.1 Legend Biotech Reports First Quarter 2023 Results and Recent Highlights New and updated data from the CARTITUDE Clinical Development Program and LEGEND-2 study evaluating ciltacabtagene autoleucel (cilta-cel) will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association’s (EHA) 2023 Hybrid Congress $350 million in gro |
|
| May 18, 2023 |
Exhibit 99.2 |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: May 18, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| May 16, 2023 |
Exhibit 99.1 Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings Eight presentations at ASCO and EHA 2023 Annual Meetings showcase continued leadership in CAR-T cell therapy research for patients with multiple myeloma across various clinical settings First analysis from the CARTITUDE-4 Phase 3 study in r |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: May 16, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: May 12, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principa |
|
| May 8, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: May 5, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princ |
|
| May 8, 2023 |
EX-4.1 Exhibit 4.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of May 5, 2023 between LEGEND BIOTECH CORPORATION, a Cayman Islands exempted company (the “Company”), , solely in its individual capacity or solely in its capacity as investment adviser, as set forth herein (“”), and each of the purchasers identified on Schedule A attached hereto (inc |
|
| May 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Ordinary Shares, $0. |
|
| May 8, 2023 |
EX-99.1 Exhibit 99.1 Legend Biotech Corporation Announces Pricing of Registered Direct Offering of US$350 million of American Depositary Shares SOMERSET, NJ – May 8, 2023 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it has agreed t |
|
| May 8, 2023 |
5,468,750 American Depositary Shares Representing 10,937,500 ordinary shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257609 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 1, 2021) 5,468,750 American Depositary Shares Representing 10,937,500 ordinary shares We are offering 5,468,750 ADSs directly to certain investors in this offering at a price per ADS of $64.00. Each ADS represents two ordinary shares, $0.0001 par value per share. Thi |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: April 21, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| April 21, 2023 |
Exhibit 99.1 Background: CARTITUDE-4 is a global, phase 3, randomized, controlled trial (NCT04181827) of ciltacabtagene autoleucel (cilta-cel), a dual-binding, B-cell maturation antigen-targeting chimeric antigen receptor (CAR)-T cell therapy, versus (vs) standard of care (SOC; pomalidomide, bortezomib, and dexamethasone [PVd] or daratumumab, pomalidomide, and dexamethasone [DPd]) in lenalidomide- |
|
| April 21, 2023 |
Exhibit 99.2 Background: Heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM) treated with standard of care therapy have median overall survival (OS) of ~12 months. In the single- arm, phase 1b/2 CARTITUDE-1 study (NCT03548207), patients received a single infusion of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor-T cell therapy targeting B- cell maturati |
|
| April 21, 2023 |
Exhibit 99.3 Background: LCAR-B38M CAR-T cells express a structurally differentiated chimeric antigen receptor (CAR) construct containing a 4-1BB costimulatory domain and 2 BCMA-targeting single-domain antibodies designed to confer avidity. LEGEND-2 was a first-in-human phase 1 study of LCAR-B38M conducted in China, which showed encouraging efficacy and manageable safety in 74 patients with relaps |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: April 19, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: April 18, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: April 14, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| April 14, 2023 |
Exhibit 99.1 [***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. MASTER TECHNOLOGY TRANSFER, MANUFACTURING AND CLINICAL SUPPLY SERVICES AGREEMENT FOR BCMA CAR-T PRODUCT This Master Technology Transfer, Manufacturing and Clinical Supply Services Agreement for BCMA CAR-T |
|
| April 3, 2023 |
Legend Biotech Establishes Strategic Advisory Board Exhibit 99.1 Legend Biotech Establishes Strategic Advisory Board SOMERSET, N.J.-(BUSINESS WIRE)-April 3, 2023-Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the formation of a strategic advisory board and the appointments o |
|
| April 3, 2023 |
6-K 1 a53373375.htm LEGEND BIOTECH 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: April 3, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerse |
|
| March 30, 2023 |
EXHIBIT 4.15 [***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed Private & Confidential DATED 7 December 2020 LEGEND BIOTECH USA, INC and LEGEND BIOTECH IRELAND LIMITED and JANSSEN BIOTECH, INC. AMENDMENT NO. 3 TO COLLABORATION AND LICENSE AGREEMENT DATED DECEMBER 21, 2 |
|
| March 30, 2023 |
EXHIBIT 4.18 Execution Version [***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed Private & Confidential DATED July 7, 2022 LEGEND BIOTECH USA, INC. and LEGEND BIOTECH IRELAND LIMITED and JANSSEN BIOTECH, INC. and JANSSEN PHARMACEUTICA NV AMENDMENT NO. 9 TO COLLABORATI |
|
| March 30, 2023 |
Principal Financial Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lori Macomber, certify that: 1.I have reviewed this annual report on Form 20-F (this “report”) of Legend Biotech Corp.(the “Company”); 2.Based on my knowledge, this report does not contain any untrue |
|
| March 30, 2023 |
Consent of Ernst & Young Hua Ming LLP, an independent registered public accounting firm. EXHIBIT 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Post-Effective Amendment No. 1 to the Registration Statement (Form S-8 No. 333-239478) pertaining to the Share Option Scheme and the 2020 Restricted Shares Plan of Legend Biotech Corporation, (2) Registration Statement (Form F-3 No.333-257 |
|
| March 30, 2023 |
Principal Executive Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ying Huang, certify that: 1.I have reviewed this annual report on Form 20-F (this “report”) of Legend Biotech Corp.(the “Company”); 2.Based on my knowledge, this report does not contain any untrue sta |
|
| March 30, 2023 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act Exhibit 2.5 Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act As of December 31, 2022, Legend Biotech Corporation (the “Company,” “we,” “us” and “our”) had the following series of securities registered pursuant to Section 12 of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American depositary shares, each |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: March 30, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princi |
|
| March 30, 2023 |
EXHIBIT 4.13 December 10, 20 l 8 Legend Biotech Ireland Limited One Spenser Dock, North Wall Quay Dublin, Ireland Attention: General Manager Legend Biotech USA, Inc. 10 Knightsbridge Road Piscataway, Township, NJ 08854 Attention: General Manager CONFIDENTIAL RE: Letter Agreement No. 2 to the Collaboration and License Agreement By and Among Legend Biotech USA, Inc. ("Legend U.S.), Legend Biotech Ir |
|
| March 30, 2023 |
EXHIBIT 4.16 [***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed Private & Confidential DATED 26 July 2021 LEGEND BIOTECH USA, INC and LEGEND BIOTECH IRELAND LIMITED and JANSSEN BIOTECH, INC. and JANSSEN PHARMACEUTICA NV AMENDMENT NO. 6 TO COLLABORATION AND LICENSE AGRE |
|
| March 30, 2023 |
EXHIBIT 4.12 [***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. February 26, 2018 Legend Biotech Ireland Limited One Spencer Dock, North Wall Quay Dublin, Ireland Attention: General Manager Legend Biotech USA, Inc. 10 Knightsbridge Road Piscataway Township, NJ 08854 A |
|
| March 30, 2023 |
Legend Biotech Reports Full-Year 2022 Results and Recent Highlights Exhibit 99.1 Legend Biotech Reports Full-Year 2022 Results and Recent Highlights CARTITUDE-4, a Phase 3 study of CARVYKTI® (ciltacabtagene autoleucel) meets primary endpoint at the study’s first pre-specified interim analysis FDA clearance of IND application for LB2102 in Extensive Stage Small Cell Lung Cancer (SCLC) CARVYKTI® (ciltacabtagene autoleucel) receives approval from Japan’s Ministry of |
|
| March 30, 2023 |
regarding change in independent registered public accounting firm. EXHIBIT 16.1 March 30, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read the statement made by Legend Biotech Corporation in Item 16F in its Form 20-F dated March 30, 2023 and are in agreement with the statements contained in the first to fourth paragraphs of Item 16F (a) with reference to us therein. We have no basis to agree or dis |
|
| March 30, 2023 |
LLP, an independent registered public accounting firm. EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Post-Effective Amendment No. 1 to the Registration Statement (Form S-8 No. 333-239478) pertaining to the Share Option Scheme and the 2020 Restricted Shares Plan of Legend Biotech Corporation, (2) Registration Statement (Form F-3 No.333-257 |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| March 30, 2023 |
Principal Executive Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Legend Biotech Corp. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ying Hua |
|
| March 30, 2023 |
EXHIBIT 15.3 March 29, 2023 VIA EDGAR Division of Corporate Finance U.S. Securities & Exchange Commission 100 F. Street, NE Washington, D.C. 20549 Re: Legend Biotech Corporation Submission under Item 16I(a) of Form 20-F Attn: Division of Corporate Sciences Office of Life Sciences Dear Sir/Madam, In compliance with the Holding Foreign Companies Accountable Act, Legend Biotech Corporation (the “Comp |
|
| March 30, 2023 |
EXHIBIT 4.18 [***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed Private & Confidential DATED 11 November 2021 LEGEND BIOTECH USA, INC and LEGEND BIOTECH IRELAND LIMITED and JANSSEN BIOTECH, INC. AMENDMENT NO. 7 TO COLLABORATION AND LICENSE AGREEMENT DATED DECEMBER 21, |
|
| March 30, 2023 |
EXHIBIT 4.15 [***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. Private & Confidential DATED 30 November 2020 LEGEND BIOTECH USA, INC and LEGEND BIOTECH IRELAND LIMITED and JANSSEN BIOTECH, INC. AMENDMENT NO. 2 TO COLLABORATION AND LICENSE AGREEMENT DATED DECEMBER 21, |
|
| March 30, 2023 |
Principal Financial Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Legend Biotech Corp. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lori Mac |
|
| February 17, 2023 |
Principal Executive Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with this Amendment No. 1 to the Annual Report of Legend Biotech Corp. (the “Company”) on Form 20-F/A for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof ( |
|
| February 17, 2023 |
Principal Financial Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lori Macomber, certify that: 1.I have reviewed this Amendment No. 1 to the annual report on Form 20-F/A (this “report”) of Legend Biotech Corp. (the “Company”); 2.Based on my knowledge, this report do |
|
| February 17, 2023 |
Principal Executive Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ying Huang, certify that: 1.I have reviewed this Amendment No. 1 to the Annual Report on Form 20-F/A (this “report”) of Legend Biotech Corp. (the “Company”). 2.Based on my knowledge, this report does |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Amendment No. 1) (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| February 17, 2023 |
Consent of Ernst & Young Hua Ming LLP, an independent registered public accounting firm. EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Post-Effective Amendment No. 1 to the Registration Statement (Form S-8 No. 333-239478) pertaining to the Share Option Scheme and the 2020 Restricted Shares Plan of Legend Biotech Corporation, (2) Registration Statement (Form F-3 No.333-257 |
|
| February 17, 2023 |
Principal Financial Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with this Amendment No. 1 to the Annual Report of Legend Biotech Corp. (the “Company”) on Form 20-F/A for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof ( |
|
| February 17, 2023 |
6-K 1 lgn-202263022x6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: February 17, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, N |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: February 17, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 0 |
|
| February 14, 2023 |
SC 13G/A 1 p23-0209sc13ga.htm LEGEND BIOTECH CORP SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Legend Biotech Corporation (Name of Issuer) Ordinary Shares, par value of $0.0001 per share (Title of Class of Securities) 52490G102** (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Sta |
|
| February 14, 2023 |
LEGN / Legend Biotech Corp / AquaPoint L.P. - SC 13G/A Passive Investment SC 13G/A 1 d450084dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Legend Biotech Corporation (Name of Issuer) Ordinary Shares (Title of Class of Securities) 52490G102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box |
|
| February 14, 2023 |
LEGN / Legend Biotech Corp / Zhang Fangliang - SC 13G/A Passive Investment SC 13G/A 1 d449415dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Legend Biotech Corporation (Name of Issuer) Ordinary Shares (Title of Class of Securities) 52490G102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate bo |
|
| February 14, 2023 |
LEGN / Legend Biotech Corp / GenScript Biotech Corp - SC 13G/A Passive Investment SC 13G/A 1 d433447dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Legend Biotech Corporation (Name of Issuer) Ordinary Shares (Title of Class of Securities) 52490G102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: January 27, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| January 27, 2023 |
Exhibit 99.1 Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma SOMERSET, N.J.-(BUSINESS WIRE)-January 27, 2023-Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel |
|
| January 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: January 24, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: January 9, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princ |
|
| January 9, 2023 |
Legend Biotech Announces Notification of Delinquency from The Nasdaq Stock Market LLC Exhibit 99.1 Legend Biotech Announces Notification of Delinquency from The Nasdaq Stock Market LLC SOMERSET, N.J.-(BUSINESS WIRE)-January 9, 2023-Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that it received a notice (the |
|
| January 3, 2023 |
Exhibit 99.1 Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China SOMERSET, N.J.-(BUSINESS WIRE)-January 2, 2023-Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that China?s Nationa |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: January 2, 2023 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princ |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: December 8, 2022 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| December 8, 2022 |
Exhibit 99.1 Preclinical Phase 1 GASTRIC, ESOPHAGEAL & PANCREATICt (CLAUDIN 18.2) Auto logous NCT04467853 RRMM (BCMA) LEGEND-2t Auto logous NCT03090659 IGlobal IUS I China Phase 2 MMt (BCMA) Al logeneic - CAR-NK NCT05498545 MMt (BCMA) A llogeneic - CAR-yo T NCT05376345 NHLt /ALLt (CD19 X CD20 X CD22}t Auto logous NCT05318963 NCT05292898 Hect (GPC3) Auto logous NCT05352542 The safety and efficacy o |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: November 22, 2022 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of pri |
|
| November 22, 2022 |
Amendment No. 3 to Interim Supply Agreement, dated as of November 16, 2022 Exhibit 10.2 Execution Version Confidential AMENDMENT NO. 3 TO INTERIM PRODUCT SUPPLY AGREEMENT This Amendment No. 3 to the Interim Product Supply Agreement (this ?Amendment?) is made and effective as of November 16, 2022 (the ?Amendment Effective Date?), by and among Legend Biotech USA Inc., a Delaware corporation (?Legend?), and Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (?JPI?). |
|
| November 22, 2022 |
Amendment No. 2 to Interim Supply Agreement, dated as of October 17, 2022 Exhibit 10.1 Execution Version Confidential AMENDMENT NO. 2 TO INTERIM PRODUCT SUPPLY AGREEMENT This Amendment No. 2 to the Interim Product Supply Agreement (this ?Amendment?) is made and effective as of October 17, 2022 (the ?Amendment Effective Date?), by and among Legend Biotech USA Inc., a Delaware corporation (?Legend?), and Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (?JPI?). C |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: November 21, 2022 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of pri |
|
| November 21, 2022 |
Exhibit 99.1 Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer SOMERSET, N.J.-(BUSINESS WIRE)-November 21, 2022-Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that the U.S. Food and |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: November 4, 2022 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| November 4, 2022 |
Legend Biotech Announces Participation in Upcoming Investor Conferences Exhibit 99.1 Legend Biotech Announces Participation in Upcoming Investor Conferences SOMERSET, N.J.-(BUSINESS WIRE)-November 4, 2022-Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences: Event: |
|
| November 3, 2022 |
Exhibit 99.1 Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022 Seven accepted poster presentations showcase our continued leadership in CAR-T cell therapy research for patients with multiple myeloma New analysis of sustained minimal residual disease (MRD) negativity from the pivotal CARTITUDE-1 study of CARVYKTI? (ciltacabtagene autoleucel, ci |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K 6-K 1 a52959680.htm LEGEND BIOTECH CORPORATION 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: November 3, 2022 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottonta |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: October 20, 2022 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: October 18, 2022 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: October 17, 2022 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of prin |
|
| October 17, 2022 |
Voting Results of 2022 Annual General Meeting Exhibit 99.1 Voting Results of 2022 Annual General Meeting At Legend Biotech Corporation?s (the ?Company?) annual general meeting of shareholders held on October 14, 2022 (the ?AGM?), the Company?s shareholders: ? received the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2021; ? ratified the appointment of Ernst & Young LLP as the Company?s indepe |
|
| October 11, 2022 |
CORRESP 1 filename1.htm October 11, 2022 Office of Life Sciences Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attn: Dillon Hagius Jason Drory Li Xiao Daniel Gordon Re: Legend Biotech Corporation Form 20-F for Fiscal Year Ended December 31, 2021 Response Dated September 30, 2022 File No. 001-39307 Ladies and Gentlemen: On behalf of ou |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: October 3, 2022 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of princ |
|
| October 3, 2022 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the ?Agreement?) is made by and between Legend Biotech USA Inc. (?Legend Biotech USA?), together with its subsidiaries and parent company, Legend Biotech Corporation (?Parent?) (collectively the ?Company?), and Lori Macomber (the ?Executive?) (together, the ?Parties?) and is effective as of the E |
|
| September 30, 2022 |
CORRESP 1 filename1.htm Mark Ballantyne T: +1 703 456 8084 [email protected] Via EDGAR September 30, 2022 Office of Life Sciences Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attn: Dillon Hagius Jason Drory Li Xiao Daniel Gordon Re: Legend Biotech Corporation Form 20-F for Fiscal Year Ended December 31, 2021 Filed March 31, 2022 |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: September 27, 2022 Commission File Number: 001-39307 Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of pr |
|
| September 27, 2022 |
Exhibit 99.1 CARVYKTI? (ciltacabtagene autoleucel) Receives Approval from Japan?s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma SOMERSET, N.J.-(BUSINESS WIRE)-September 27, 2022-Legend Biotech Corporation (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat li |
